|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Synthetic Biology and the Environmentalmost 6 years ago
Measuring Pharma’s Wider Mandatealmost 6 years ago
Patients as the North Staralmost 6 years ago
Going Public During Lockdown: IPO Insights from Five Biotechnology CFOsalmost 6 years ago
A Rare-Disease Must? Building Long-Term Relationshipsalmost 6 years ago
Making Remote Work a Success Beyond COVIDalmost 6 years ago
CRISPR for Diversity, and Humanity’s, Sakealmost 6 years ago
Expediting the Cancer Treatment Pathalmost 6 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesalmost 6 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
3
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
4
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
5